Previous evidence suggests the existence of a thyroid hormone-IGF axis in the liver and changes in hepatic insulin-like growth factor binding protein (IGFBP) expression in rats with altered thyroid status have been previously reported.
Introduction
The insulin-like growth factors (IGF-I and -II) are polypeptide hormones, similar in structure to proinsulin, which play important roles in cell growth and differentiation. The IGFs are found, in the circulation and in the extracellular fluids, bound to specific high-affinity binding proteins (IGFBP-1 to -6) that are unrelated to either type of the IGF-receptors. The IGFBPs are potent modulators of IGF actions on target cells and have been reported both to inhibit and to potentiate IGF activity (Froesch et al. 1985 , Rechler 1993 , Jones & Clemmons 1995 .
The components of the IGF/IGFBP system are produced by different cells and tissues, the liver being one of the major sites of synthesis. The levels of IGFBPs in serum and IGFBP mRNAs in liver are highly regulated by metabolic and hormonal factors as well as by the developmental age.
In adult rat serum, most of the IGFs circulate as a 150-kDa ternary complex that consists of IGF-I, IGFBP-3 and an acid-labile subunit (ALS). In contrast, in fetal rat serum there are high levels of IGF-II and the most abundant binding protein is IGFBP-2 (Lund et al. 1986 , Donovan et al. 1989 , Ooi et al. 1990 , Albiston & Herington 1992 .
In the rat, IGFBP-2 mRNA has been detected in several fetal tissues, the highest levels being in the liver (Brown et al. 1989) . Although message levels are barely detectable in adult liver, relatively high levels persist in adult brain, testes, ovaries and kidney (Margot et al. 1989) .
The factor(s) responsible for the regulation of IGFBP-2 mRNA within rat tissues are not well defined. Hepatic IGFBP-2 transcript is increased by hormonal and metabolic manipulation of adult animals such as fasting, hypophysectomy and diabetes (Böni-Schnetzler et al. 1989 , Margot et al. 1989 , Orlowski et al. 1990 , Ooi et al. 1990 , Tseng et al. 1992 . Interestingly, the increase after hypophysectomy is not normalized by growth hormone (GH) treatment (Margot et al. 1989 , Ooi et al. 1990 , suggesting a possible involvement of other hormones regulated by pituitary secretion. A candidate for this role could be thyroid hormone: it has been demonstrated that thyroid hormone withdrawal increases the expression of IGFBP-2, in both developing and adult rat liver (Näntö-Salonen et al. 1991 , Rodriguez-Arnao et al. 1994 . GH replacement in hypothyroid animals did not correct the increase in IGFBP-2 message, suggesting a possible direct regulation of this gene by thyroid hormone (Näntö-Salonen et al. 1993) .
We have recently demonstrated a tri-iodothyronine (T 3 )-induced increase in IGFBP-4 expression in a rat hepatocyte model, in total agreement with the in vivo effects of thyroid hormone withdrawal from or administration to the rats (Demori et al. 1997) . In the same experiments, we were unable to obtain evidence of an effect of T 3 on IGFBP-2 expression, because of the barely detectable level of IGFBP-2 message in cultured hepatocytes from adult rats.
In the present study, we used the in vitro model of primary hepatocytes isolated from hypothyroid rats, which express high levels of IGFBP-2 mRNA, enabling us to demonstrate the direct regulation of IGFBP-2 expression by T 3 .
Materials and Methods

Animals
Adult male Wistar rats were rendered hypothyroid by the addition of 0·05% propylthiouracil (PTU) or 0·05% methimazole (MMI) to the drinking water from the 6th to the 15th week of age. Age-matched rats receiving regular drinking water served as controls. During the last week before being killed, groups of both hypothyroid and control rats were treated daily with i.p. injections of T 3 (15 µg/100 g body weight).
Animals were killed by cervical dislocation. Blood was collected, allowed to clot and the serum stored at 80 C. Serum T 3 and thyroxine (T 4 ) were evaluated by an enhanced chemiluminescent (ECL) enzyme immunoassay (DPC, Los Angeles, CA, USA). The limit of detection of the assay was 0·35 ng/ml for T 3 and 4 ng/ml for T 4 .
Immediately after death of the rat, the liver was promptly removed, quickly frozen in liquid nitrogen and stored at 80 C until required for use.
Hepatocyte primary cultures
Male Wistar rats rendered hypothyroid by PTU administration were used to isolate hepatocytes by a standardized collagenase (type I, Sigma Chemical Co., St Louis, MO, USA) perfusion technique as previously described (Fugassa et al. 1983) . Cells (viability d85% by trypan blue exclusion) were resuspended at a concentration of 5 10 5 cells/ml in serum-free Dulbecco's modified Eagle's medium (DMEM) supplemented with essential and nonessential amino acids, insulin (0·1 U/ml) and dexamethasone (10 6 M). Next, 8 ml of this cell suspension were plated on collagen (type III, Sigma)-coated 100-mm plastic dishes (Costar, Cambridge, MA, USA). After 90 min, medium with unattached cells was aspirated and monolayers were exposed to DMEM containing 0·25% BSA (fraction V, cell culture tested, Sigma). Specific experiments were begun on cultures that had been incubated for 24 h of adaptation to the in vitro environment (time 0). T 3 (Sigma) was added to the culture medium at indicated concentrations. Insulin (Actrapid HM, Novo Nordisk, Bagsvaerd, Denmark) was added to the culture medium at the concentration of 10 8 M. The protein synthesis inhibitors, cycloheximide (0·1 µg/ml; Sigma) and anisomycin (2·65 µg/ml; Sigma), were added to the cultures 1 h before the addition of T 3 . The transcription inhibitor, actinomycin D (Sigma), was used at a concentration of 5 µg/ml. PTU (Sigma) was used at a dose of 5·8 10 9 M (Cook et al. 1983 ). Cell viability was not affected by the duration of the culture or by the addition of drugs to the medium, as checked by trypan blue exclusion test.
At the indicated times, culture medium was removed; monolayers were quickly washed twice with ice-cold sterile PBS, immediately frozen in liquid nitrogen and stored at 80 C until used for RNA extraction.
RNA isolation
Total RNA was prepared using acid guanidinium thyocyanate-phenol-chloroform extraction (Chomczynski & Sacchi 1987) . RNA was quantified by measuring absorbance at 260 nm. Samples were stored at 80 C until required for use.
cDNA probes
The rat IGFBP-2 (Brown et al. 1989) cDNA probe was kindly provided by Dr S Shimasaki, Department of Cell Biology, The Scripps Research Institute, La Jolla, CA, USA. The human glyceraldehyde-3-phosphate dehydrogenase (G3PDH) cDNA probe was purchased from Clontech Laboratories Inc., Palo Alto, CA, USA. The rat 18S rDNA probe (BamHI-HindIII fragment, Chan et al. 1984) was generously provided by Dr I G Wool, Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL, USA. The probes were labelled to high specific radioactivity by multiprime DNA labelling systems (Amersham International plc, Amersham, Bucks, UK) using [ 32 P]dCTP (NEN Du Pont, Du Pont De Nemours GmbH, Bad Homburg, Germany; specific radioactivity 3000 Ci/mmol).
Northern blot analysis
Total RNA (20 µg) was fractionated by loading on 1% agarose gel containing 2·2 M formaldehyde in 20 mM MOPS (pH 7·0), 5 mM sodium acetate and 1 mM disodium EDTA. RNA was stained with ethidium bromide to check the integrity of the samples and ensure equal loading in each lane. After transfer of the samples to nylon membrane by capillary blotting, prehybridization was performed for 2 h at 42 C in a solution containing 5 SSPE (1 SSPE=0·15 M NaCl-0·01 M NaH 2 PO 4 -1 mM EDTA), 50% formamide, 5 Denhardt's solution, 0·5% SDS and 100 µg/ml denatured salmon sperm DNA (Sambrook et al. 1989) . Hybridization was carried out for 20 h at 42 C in fresh buffer containing the 32 P-labelled probe. After hybridization, the filters were washed sequentially in 2 SSPE, 0·1% SDS, 1 SSPE, 0·1% SDS and 0·1 SSPE, 0·1% SDS at 42 C, each wash lasting for 20 min. Filters were then exposed to Amersham Hyperfilm-MP films at 80 C using intensifying screens.
To ensure even loading, the membranes were stripped and rehybridized with either a human G3PDH cDNA probe or a rat 18S rDNA probe.
The signal intensity of the autoradiograms was quantified densitometrically using the Scion ImagePC software package. Arbitrary densitometric units were normalized to G3PDH or 18S and expressed as a percentage of the control values.
IGFBP-2 determination in serum and conditioned medium
IGFBP-2 concentrations in rat serum and hepatocyte conditioned medium were measured by RIA (DSL, Webster, Texas, USA), with a limit of detection of 0·5 ng/ml.
Statistical analyses
Data are presented as the mean ... Statistical significance was analysed using ANOVA with the multiple group comparison test of Scheffé. Differences were regarded as significant when Pc0·05.
Results
IGFBP-2 mRNA levels in cultured hepatocytes
Hepatocytes were incubated for 24 h to allow adaptation to the in vitro environment, then transferred into fresh DMEM supplemented as described under Materials and Methods. At different times, total RNA was extracted and analysed for the presence of IGFBP-2 mRNA by Northern blot hybridization. As shown in Fig. 1 , Northern blot analysis revealed barely detectable IGFBP-2 mRNA in normal rat hepatocytes, according to Arany et al. (1993) . In contrast, when cells were prepared from PTU-treated hypothyroid rats, the IGFBP-2 message was readily detected. No direct effect of PTU on IGFBP-2 mRNA levels was seen when the drug was added to the culture medium of normal hepatocytes. Therefore, the effect of T 3 was investigated using cultured hepatocytes isolated from hypothyroid rats. Figure 2 shows the characteristic 1·5 kb IGFBP-2 message expressed by rat hepatocytes cultured for up to 24 h after the first 24 h of adaptation to the culture conditions. It appears that IGFBP-2 mRNA levels increased with the time in culture. When 10 6 M T 3 was present in the culture medium for 12-24 h, the abundance of IGFBP-2 mRNA was significantly enhanced (P<0·001).
Effect of T 3 on IGFBP-2 expression in cultured hepatocytes
IGFBP-2 concentration in conditioned media of hepatocytes cultured for 12 h was 11·5 1·8 ng/ml, and this value was increased in 10 6 M T 3 -treated cells (19·7 1·7 ng/ml, Pc0·03), consistent with what was observed at the mRNA level. Figure 3 shows the levels of IGFBP-2 mRNA after the addition of T 3 to the culture medium to final concentrations ranging from 10 10 to 10 6 M. After 12 h of exposure, the maximal increase in IGFBP-2 mRNA levels was elicited by 10 6 -10 8 M T 3 , whereas 10 9 and 10 10 M were ineffective.
Effect of cycloheximide and anisomycin on T 3 -induced IGFBP-2 mRNA levels in cultured hepatocytes
Hepatocytes were cultured for 12 h in the presence of either cycloheximide (0·1 µg/ml) or anisomycin (2·65 µg/ ml), which both inhibit de novo protein synthesis. The inhibitors were used at doses that did not decrease cell viability over the time of incubation, but were able to inhibit protein synthesis in cultured hepatocytes by 90-97% (Barreca et al. 1992 , Messina 1991 . As shown in Fig. 4 , the presence of cycloheximide or anisomycin in the culture medium resulted in increased Representative autoradiograms of Northern blots showing 1·5 kb IGFBP-2 mRNA, 1·3 kb G3PDH mRNA and 1·9 kb 18S rRNA. Lanes: 1, adult rat liver; 2, hypothyroid rat liver; 3, adult rat hepatocytes cultured for 24 h; 4, adult rat hepatocytes cultured for 24 h in the presence of 10 6 M T 3 ; 5, hypothyroid rat hepatocytes cultured for 24 h; 6, hypothyroid rat hepatocytes cultured for 24 h in the presence of 10 6 M T 3 ; 7, adult rat hepatocytes cultured for 24 h; 8, adult rat hepatocytes cultured for 24 h in the presence of 5·8 10 9 M PTU.
overall amount of IGFBP-2 mRNA, but did not affect the effect of T 3 on the specific transcript.
Effect of actinomycin D on T 3 -induced IGFBP-2 mRNA levels in cultured hepatocytes
To check the effect of T 3 on IGFBP-2 mRNA stability, hepatocytes were cultured for 12 h in the absence or presence of T 3 to achieve the induction of IGFBP-2 mRNA, and then exposed to actinomycin D (5 µg/ml), a potent inhibitor of transcription, in order to evaluate IGFBP-2 mRNA decay. As shown in Fig. 5 , both control and T 3 -treated hepatocytes showed stable IGFBP-2 mRNA levels, even after 12 h of incubation with actinomycin D. Owing to the lack of decay of IGFBP-2 mRNA, it was impossible to evaluate its half-life and consequently the effect of T 3 on IGFBP-2 mRNA stability.
As shown in Fig. 6 , the presence of actinomycin D along with T 3 in the culture medium of hepatocytes cultured for 12 h prevented the T 3 -induced increase in IGFBP-2 mRNA levels, suggesting a transcriptional regulation of IGFBP-2 gene by T 3 .
Effect of insulin on T 3 -induced IGFBP-2 mRNA levels in cultured hepatocytes
It has been reported that insulin decreases IGFBP-2 mRNA levels in cultured hepatocytes (Böni-Schnetzler et al. 1990) . We tested the effect of the pancreatic hormone on basal and T 3 -induced IGFBP-2 expression in our culture system. As can be seen in Fig. 7 , the presence of 10 8 M insulin in the culture medium for 12 h resulted in decreased levels of IGFBP-2 message. When insulin was present in the culture medium of hepatocytes together with T 3 , the stimulatory effect of the latter hormone was completely abolished.
Effect of T 3 administration on IGFBP-2 expression in rat liver
The finding that hepatic IGFBP-2 expression is enhanced in vivo by thyroid hormone withdrawal and in vitro by addition of T 3 to the culture medium of hepatocytes from hypothyroid rats induced us to verify the effects of T 3 administration to both hypothyroid and euthyroid rats.
Groups of control and hypothyroid rats were injected daily with T 3 (15 µg/100 g body weight) during the last week before death.
Serum T 3 and T 4 levels of the animals are reported in Table 1 . PTU treatment always resulted in lower serum concentrations of thyroid hormone with respect to controls. The same results were obtained when the rats were treated with MMI (not shown). T 3 treatment induced high serum T 3 concentrations, associated with low serum concentration of T 4 . Figure 8 shows that PTU-induced hypothyroidism was associated with enhanced expression of hepatic IGFBP-2 mRNA. T 3 treatment decreased hepatic IGFBP-2 mRNA to about 50% of the levels of hypothyroid rat liver. When T 3 was given to control rats, the hepatic IGFBP-2 signal was faint but reproducible and significantly greater compared with the undetectable signal in control livers. The changes in IGFBP-2 levels in the serum of the same rats paralleled those of the hepatic mRNA in all conditions tested ( Table 2) .
As shown in Fig. 9 , the amount of IGFBP-2 mRNA was increased in the liver of MMI-treated hypothyroid rats compared with controls. The abundance of the IGFBP-2 transcript in the liver of T 3 -replaced rats was lower than that in hypothyroid animals, but higher with respect to controls. A similar pattern was observed for serum IGFBP-2 levels (not shown).
Discussion
In the rat, the IGFBPs are produced by different tissues and cell types under a complex and specific regulation by hormonal, nutritional and developmental factors. During fetal and early postnatal life, the liver produces high levels of IGFBP-2, but within the first 3 weeks after birth hepatic IGFBP-2 production strongly decreases to the barely detectable levels typical of the adult rat. It has been reported that congenital hypothyroidism delays the decline of hepatic IGFBP-2 expression after birth (Näntö-Salonen et al. 1991) , and an increase in hepatic IGFBP-2 mRNA has also been observed in rats rendered hypothyroid in adulthood (Rodriguez-Arnao et al. 1994) . Therefore, thyroid hormone appears to play a role in regulating hepatic IGFBP-2 production in newborn and adult rats. However, our previous attempts to demonstrate a direct effect of T 3 on IGFBP-2 expression were ineffective (Demori et al. 1997) .
In the present study, we have analysed the effect of T 3 on hepatic IGFBP-2 expression using cultured hepatocytes isolated from hypothyroid adult rats, in which the IGFBP-2 message is easily detectable and the sensitivity to exogenous T 3 may be greater than that of cells from euthyroid animals (Mariash & Oppenheimer 1983) .
The typical 1·5 kb IGFBP-2 mRNA was clearly expressed by hepatocytes from hypothyroid rats cultured for up to 24 h. The addition of T 3 to the hepatocyte culture medium increased the abundance of IGFBP-2 message, to about 300% with respect to control cells. The stimulation was highly significant after 12-24 h of incubation with T 3 in doses ranging from 10 8 to 10 6 M. IGFBP-2 peptide production also was stimulated in T 3 -treated cells.
The effect of T 3 on IGFBP-2 mRNA appeared to be independent of ongoing protein synthesis, as it was not abolished by the protein synthesis inhibitors, cycloheximide or anisomycin. The finding that the overall amount of IGFBP-2 transcript was greater in cells treated with cycloheximide or anisomycin could suggest the existence of a labile repressor protein that disappears when protein synthesis is blocked. However, direct evidence for the existence of such a protein is lacking.
The increase in IGFBP-2 mRNA steady state levels in T 3 -treated cells could be due to enhanced transcription of the gene, greater stability of the transcript, or both. In order to clarify these points, we tested the effect of the transcription inhibitor, actinomycin D, on IGFBP-2 mRNA abundance. Our results suggest a transcriptional regulation of the IGFBP-2 gene by T 3 : when hepatocytes were treated with the hormone along with actinomycin D to block gene transcription, the stimulation of IGFBP-2 expression was abolished. Moreover, when actinomycin D was used in order to evaluate the IGFBP-2 mRNA half-life, the message showed stable levels both in T 3 -treated and in control cells, and no decay of the signal was apparent, so that a stabilizing effect of T 3 on IGFBP-2 mRNA seems unlikely.
The presence of a thyroid hormone response element in the promoter region of the rat IGFBP-2 gene has not been documented, but a specific stimulation of IGFBP-2 expression by T 3 in osteoblasts has been observed (Schmid et al. 1992a). Other hormonal factors, also, such as retinoic acid and dexamethasone, which act via nuclear receptors belonging to the steroid/thyroid receptor superfamily, have been reported to regulate IGFBP-2 expression in different cells (Schmid et al. 1992b , Ernst & White 1996 . However, the dominant regulator of IGFBP-2 mRNA levels in hepatocytes is considered to be insulin. When added to primary cultures of liver cells, insulin strongly decreases IGFBP-2 mRNA levels (Böni-Schnetzler et al. 1990 ). This result was also confirmed in our hepatocyte cultures from hypothyroid rats. We have demonstrated, in addition, that the inhibitory effect of insulin is dominant over the action of T 3 : when both hormones are present in hepatocyte culture medium, the stimulatory effect of T 3 on IGFBP-2 expression is suppressed.
The finding that the abundance of IGFBP-2 mRNA is high in hepatocytes from hypothyroid rats and that T 3 directly increases it even more indicates that the increase in hepatic IGFBP-2 transcript levels observed in hypothyroidism is not related directly to decreased thyroid hormone levels, but to other possible alterations associated with hypothyroidism. With our in vivo experiments, we have demonstrated that T 3 treatment of hypothyroid rats decreases hepatic IGFBP-2 transcript and serum IGFBP-2 levels to about 50% of those in hypothyroid rats. Moreover, when T 3 was given to control animals, a modest but reproducible signal was detectable in the liver and a significant increase in IGFBP-2 concentration was measured in serum. Only the latter result is in agreement with our observations in vitro, demonstrating a direct stimulation of hepatic IGFBP-2 production by T 3 .
The possibility that PTU may have a thyroid hormoneindependent effect on IGFBP-2 expression seems unlikely as, when the drug was added to the culture medium of hepatocytes isolated from euthyroid animals, no direct effect on IGFBP-2 mRNA levels was apparent. Moreover, with our in vivo experiments, we demonstrated that not only PTU-but also MMI-induced hypothyroidism was associated with enhanced expression of hepatic IGFBP-2. Therefore, the increase in IGFBP-2 expression may be due to secondary effects of hypothyroidism. As insulin is considered to be a dominant negative regulator of IGFBP-2 production by hepatocytes, and given the results of our in vitro experiments demonstrating that the inhibitory effect of insulin suppresses the stimulation of IGFBP-2 expression by T 3 , we suggest that the effects observed in vivo could be due to an interplay between insulin and thyroid hormone.
In vivo experiments indicate that hepatic IGFBP-2 message is preferentially increased in conditions of mild insulopenia, such as after hypophysectomy and fasting (Ooi et al. 1990 , Tseng et al. 1992 . Experimental hypothyroidism also represents a condition of insulin deficiency: plasma concentrations of insulin in hypothyroid rats have been reported to be reduced ( Jolin et al. 1970 , Doong et al. 1997 and peak plasma insulin responses to an intraperitoneal glucose load are lower in hypothyroid than in euthyroid rats ( Jolin & Montes 1974) . Also, in our PTU-treated rats we have confirmed a reduced tolerance to i.p. injection of glucose (not shown), similar to the findings of Jolin & Montes (1974) . Even if the metabolic alterations associated with hypothyroidism are complex, the insulin deficiency could give a clue to explain, at least in part, the increase in hepatic IGFBP-2 message in PTU-treated rats. Moreover, it can be suggested that changes in nutrient intake and protein metabolism might play a role in the regulation of hepatic IGFBP-2 expression in hypothyroidism.
If not much is known about the factors that regulate hepatic IGFBP-2 expression in vivo, even less is understood concerning its physiological role. Mice lacking IGFBP-2 by targeted gene disruption are reported to be normal (Wood et al. 1993) . IGFBP-2 appears to inhibit IGF actions, particularly those of IGF-II, although in certain specific cell types it can be a modest stimulator of IGF-I action ( Jones & Clemmons 1995) . In general, the IGFBP family provides a remarkably versatile regulatory system for the IGFs and the factors capable of modulating IGFBP expression could in turn regulate IGF actions.
In conclusion, this study has demonstrated a direct stimulation of hepatic IGFBP-2 expression by thyroid hormone although, in vivo, other factors, such as insulin, appear to be involved in the regulation of hepatic IGFBP-2 in different thyroid status.
Taken together with our previous data (Demori et al. 1997) , the results presented in this paper provide further evidence that thyroid hormone interacts with the hepatic IGF system directly at the level of IGFBPs, and support a role for a thyroid hormone-IGF axis.
